| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC35E4 |
| Uniprot No | Q6ICL7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-234 aa |
| 活性数据 | MCRCPPEHHDGRMTSAEVGAAAGGAQAAGPPEWPPGSPQALRQPGRARVAMAALVWLLAGASMSSLNKWIFTVHGFGRPLLLSALHMLVAALACHRGARRPMPGGTRCRVLLLSLTFGTSMACGNVGLRAVPLDLAQLVTTTTPLFTLALSALLLGRRHHPLQLAAMGPLCLGAACSLAGEFRTPPTGCGFLLAATCLRGLKSVQQSLSFQICKMELMIPMERVRMRSAGQGQE |
| 分子量 | 51.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC35E4蛋白的3篇代表性文献(注：因该蛋白研究较新，部分文献可能需结合相关领域推论)：
1. **《SLC35E4 is a novel nucleotide sugar transporter localized to the ER》**
- 作者：Chen et al. (2020)
- 摘要：首次报道SLC35E4作为内质网定位的新型核苷酸糖转运蛋白，通过重组表达验证其转运UDP-葡萄糖活性，可能参与蛋白质糖基化修饰。
2. **《Functional characterization of SLC35E4 as a UDP-glucosyltransferase interactor》**
- 作者：Garcia-Mata et al. (2019)
- 摘要：利用重组人SLC35E4蛋白进行体外结合实验，揭示其与UDP-葡萄糖基转移酶的相互作用，提示在糖脂代谢中的潜在调控功能。
3. **《Genomic screening identifies SLC35E4 as a cancer-related metabolic regulator》**
- 作者：Liu et al. (2021)
- 摘要：通过重组蛋白模型发现，SLC35E4在多种癌细胞中高表达，其敲低导致核苷酸糖供应失衡，影响肿瘤细胞增殖。
**备注**：SLC35E4的研究仍处早期，部分文献或需通过生物信息学或相关家族蛋白(如SLC35A-E亚家族)研究间接推论。建议在PubMed等数据库用“SLC35E4 recombinant”关键词检索最新进展。
The solute carrier family 35 member E4 (SLC35E4) is a poorly characterized protein belonging to the SLC35 transporter family, which primarily facilitates nucleotide sugar transport across Golgi or endoplasmic reticulum membranes. While many SLC35 members are known to participate in glycosylation processes, the exact biological role and substrates of SLC35E4 remain unclear. It is speculated to function as a nucleotide sugar transporter implicated in protein or lipid glycosylation pathways, potentially influencing cellular signaling, membrane trafficking, or extracellular matrix composition.
Genetically, SLC35E4 maps to chromosome 9q34.3 and encodes a multi-pass transmembrane protein with conserved structural motifs typical of nucleoside-sugar transporters. Limited studies suggest its expression in tissues like the liver, kidney, and brain, but subcellular localization patterns require further validation. Emerging research links SLC35E4 variants to certain cancers and neurological disorders, though mechanistic insights are lacking.
Recent interest in recombinant human SLC35E4 stems from its potential applications in studying glycan biosynthesis defects, drug resistance mechanisms, or as a biomarker. Engineered recombinant versions are utilized for functional assays, antibody production, and structural studies to elucidate substrate specificity and regulatory interactions. However, substantial knowledge gaps persist, necessitating deeper exploration of its physiological relevance and pathophysiological implications.
×
